Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001437749-25-013874
Filing Date
2025-04-30
Accepted
2025-04-30 16:33:01
Documents
18
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-K/A nrxp20241231_10ka.htm   iXBRL 10-K/A 477521
2 EXHIBIT 31.1 ex_809016.htm EX-31.1 12483
3 EXHIBIT 31.2 ex_809017.htm EX-31.2 12494
  Complete submission text file 0001437749-25-013874.txt   824529

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA nrxp-20241231.xsd EX-101.SCH 5412
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrxp-20241231_def.xml EX-101.DEF 18694
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrxp-20241231_lab.xml EX-101.LAB 37209
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrxp-20241231_pre.xml EX-101.PRE 22962
20 EXTRACTED XBRL INSTANCE DOCUMENT nrxp20241231_10ka_htm.xml XML 13242
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

EIN.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-38302 | Film No.: 25896026
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)